本发明提供了一种包含无定形碳酸钙(ACC)和稳定所述碳酸钙的无定形形式的磷酸化氨基酸和磷酸化肽至少之一的组合物。特别地，该肽可选自甲壳动物的蛋白质，所述蛋白质也由本发明提供，即GAP65、GAP22、GAP21和GAP12。本发明的组合物可用在药物制剂和营养制剂中。

一种药物的或营养的组合物，其包含无定形碳酸钙(ACC)和至少一种选自磷酸丝氨酸和磷酸苏氨酸的磷酸化氨基酸成分，其中该磷酸化氨基酸稳定碳酸钙的无定形形式，并且其中该磷酸化氨基酸与钙的摩尔比在0.01-0.5的范围内。

The present invention provides a composition comprising amorphous calcium carbonate (ACC) and stabilizing at least one of the amorphous forms of phosphorylated amino acids and phosphorylated peptides of the calcium carbonate. In particular, the peptide may be selected from a crustacean protein also provided by the invention, namely GAP65, GAP22, GAP21 and GAP12. The compositions of the present invention can be used in pharmaceutical preparations and nutritional preparations.

A pharmaceutical or nutritional composition consisting of amorphous calcium carbonate (ACC) and at least one phosphorylated amino acid component selected from phosphoserine and phosphothreonine, in which the phosphorylated amino acid stabilizes the amorphous form of calcium carbonate and in which the phosphorylated amino acid has a molar ratio to calcium in the range of 0.01 to 0.5.